Table 3.
The Mutation or Abnormal Expression Frequency of BOTs-Related Genes
| Gene | SBOTs | MBOTs | |
|---|---|---|---|
| MAPK Pathway Activation56–58,63 | BRAF mutation | 23–48% | 0.0% |
| KRAS mutation | 17–39.5% | 92.3% | |
| ERBB2 mutation/Amplification | 6% | 3.8%/11.5% | |
| Claudin-1 overexpression | 26.3% | NA | |
| PI3K/AKT Pathway Activation57,64 | p53 mutation/Overexpression | Overexpression | 11.5% |
| CDKNA2 mutation | NA | 19.2% | |
| PTEN mutation | NA | 3.8% | |
| PIK3CA mutation | NA | 15.4% | |
| Hedgehog Pathway Activation74 | SHH positive expression | 42.8% | 0.0% |
| IHH positive expression | 14.3% | 0.0% | |
| DHH positive expression | 71.4% | 12.5% | |
| PTCH positive expression | 71.4% | 62.5% | |
| SMO positive expression | 42.8% | 62.5% | |
| GLI1 positive expression | 57.1% | 37.5% | |
| Clarification of Mucinous Subtype & Indicators for the Malignant Features | TFF3 strong expression66 | 0.0% | 61.4% |
| IMP3 strong expression68 | 8.3% | 42.2% |